PNC Financial Services Group Inc. Reduces Holdings in IQVIA Holdings Inc. $IQV

PNC Financial Services Group Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,960 shares of the medical research company’s stock after selling 6,731 shares during the quarter. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $8,179,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the 4th quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at $27,000. CrossGen Wealth LLC purchased a new stake in shares of IQVIA during the fourth quarter valued at $28,000. Finally, Activest Wealth Management increased its position in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. Evercore reissued an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Mizuho upped their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Stock Up 0.1%

Shares of IQV opened at $208.22 on Monday. The company has a market capitalization of $34.75 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.87 and a beta of 1.20. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $247.04. The stock’s 50-day moving average price is $188.23 and its 200-day moving average price is $187.05. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the business earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a share buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.